Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

AgeX Therapeutics Q3 EPS $(0.05) Up From $(0.07) YoY

AgeX Therapeutics (AMEX:AGE) reported quarterly losses of $(0.05) per share. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year.
byBenzinga Newsdesk
November 12, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

AgeX Therapeutics (AMEX:AGE) reported quarterly losses of $(0.05) per share. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Sorrento Therapeutics shares are trading high following FDA clearance of IND for Abivertinib in metastatic castrate resistant prostate cancer (mCRPC)

By Ragothaman Srinivasan
Today, 10:39 PM
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug application (IND) of Abivertinib (Fujovee) for patients with metastatic castrate resistant prostate cancer (mCRPC) in the Phase 2 MAVERICK clinical study.

SRNE